Visualitza per autoria "Pujana, Miguel Angel"

Ordena per: Ordre: Resultats:

  • Cancer network activity associated with therapeutic response and synergism
    Serra Musach, Jordi; Capdevila Busquets, Eva; Jaeger, Samira; Aloy, Patrick, 1972-; Pujana, Miguel Angel (BioMed Central, 2016)
    Background: Cancer patients often show no or only modest benefit from a given therapy. This major problem in oncology is generally attributed to the lack of specific predictive biomarkers, yet a global measure of cancer ...
  • Differential metabolic activity and discovery of therapeutic targets using summarized metabolic pathway models
    Çubut, Cankut; Hidalgo, Marta R.; Amadoz, Alicia; Rian, Kinza; Salavert, Francisco; Pujana, Miguel Angel; Mateo, Francesca; Herranz Ors, Carmen, 1992-; Carbonell-Caballero, Jose; Dopazo, Joaquín (Nature Research, 2019)
    In spite of the increasing availability of genomic and transcriptomic data, there is still a gap between the detection of perturbations in gene expression and the understanding of their contribution to the molecular ...
  • Genetic and genomic analysis modeling of germline c-MYC overexpression and cancer susceptibility
    Solé, Xavier; Hernández, Pilar; López de Heredia, Miguel de; Armengol i Dulcet, Lluís; Rodríguez Santiago, Benjamín; Gómez, Laia; Maxwell, Christopher A.; Aguilo, Fernando; Condom, Enric; Abril, Jesús; Pérez Jurado, Luis Alberto; Estivill, Xavier, 1955-; Nunes, Virginia; Capellá, Gabriel; Gruber, Stephen B.; Moreno, Víctor; Pujana, Miguel Angel (BioMed Central, 2008)
    Background: Germline genetic variation is associated with the differential expression of many human genes. The phenotypic effects of this type of variation may be important when considering susceptibility to common genetic ...
  • Histamine signaling and metabolism identify potential biomarkers and therapies for lymphangioleiomyomatosis
    Herranz Ors, Carmen, 1992-; Gómez Moruno, Antonio; Pujana, Miguel Angel (EMBO Press, 2021)
    Inhibition of mTOR is the standard of care for lymphangioleiomyomatosis (LAM). However, this therapy has variable tolerability and some patients show progressive decline of lung function despite treatment. LAM diagnosis ...
  • Immune cell associations with cancer risk
    Palomero, Luis; Mereu, Elisabetta; Pujana, Miguel Angel (Elsevier, 2020)
    Proper immune system function hinders cancer development, but little is known about whether genetic variants linked to cancer risk alter immune cells. Here, we report 57 cancer risk loci associated with differences in ...
  • Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast
    Maxwell, Christopher A.; Guigó Serra, Roderic; Curado, Joao; Tilgner, Hagen, 1980-; Pujana, Miguel Angel (Public Library of Science (PLoS), 2011)
    Differentiated mammary epithelium shows apicobasal polarity, and loss of tissue organization is an early hallmark of breast carcinogenesis. In BRCA1 mutation carriers, accumulation of stem and progenitor cells in normal ...
  • Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks
    Sebestyén, Endre; Singh, Babita, 1986-; Miñana Gómez, Belén; Pagès Pinós, Amadís; Mateo, Francesc; Pujana, Miguel Angel; Valcárcel, J. (Juan); Eyras Jiménez, Eduardo (Cold Spring Harbor Laboratory Press (CSHL Press), 2016)
    Alternative splicing is regulated by multiple RNA-binding proteins and influences the expression of most eukaryotic genes. However, the role of this process in human disease, and particularly in cancer, is only starting ...
  • Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition
    Mateo, Francesca; López Bigas, Núria; Pujana, Miguel Angel (Nature Publishing Group, 2017)
    Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition ...
  • VAV3 mediates resistance to breast cancer endocrine therapy
    Aguilar, Helena; Caizzi, Livia; Di Croce, Luciano; Pujana, Miguel Angel (BioMed Central, 2014)
    Introduction: Endocrine therapies targeting cell proliferation and survival mediated by estrogen receptor α (ERα) are among the most effective systemic treatments for ERα-positive breast cancer. However, most tumors initially ...

Cerca

Visualitza

El meu compte

Amb col·laboració de Complim Participem